Skip to content

Renal Perfusion and the Development of AKI Following Traumatic Injury

Renal Perfusion and the Development of AKI Following Traumatic Injury - A Longitudinal Observational Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06917053
Acronym
PERTAKI
Enrollment
20
Registered
2025-04-08
Start date
2024-04-13
Completion date
2026-07-31
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AKI - Acute Kidney Injury, AKI (Acute Kidney Injury) Due to Trauma, Traumatic Haemorrhagic Shock

Brief summary

Acute kidney injury (AKI) is a complication of traumatic haemorrhagic shock (THS) and together these conditions increase mortality risk. Although septic shock patients who develop severe AKI are known to develop hypoperfusion of the renal cortex, little is known regarding intra-renal perfusion changes in THS. The aim of the current study is to investigate the effects of THS on renal microcirculatory perfusion.

Interventions

DEVICEUltrasound (including contrast enhanced ultrasound)

Ultrasound measures: contrast enhanced ultrasound (CEUS) of the kidney, venous excess ultrasound (VExUS), echocardiography

DEVICESublingual incident dark field videomicroscopy

Sublingual incident dark field (IDF) videomicroscopy

DEVICEUrinary oxygen tension.

Continuous urinary oxygen tension

Sponsors

King's College Hospital NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Within 24 hours of ICU admission following traumatic injury * Received any blood products during initial resuscitation * Lactate \> 2 mmol/l at any stage prior to study enrolment

Exclusion criteria

* Known intolerance to Sonovue or any other ultrasound contrast agent * Patients with un-survivable injuries / not expected to survive 24 hours in whom the intent of treatment is palliative * Known CKD 4 or end stage renal failure * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Cortical mean transit time (mTT) measured in secondsMeasured at enrollment, +24 hours and + 48 hoursContrast enhanced ultrasound measure of renal cortical tissue blood flow

Secondary

MeasureTime frameDescription
Cortical perfusion index (PI) measured in arbitrary unitsMeasured at enrollment, +24 hours and + 48 hoursContrast enhanced ultrasound measures of renal cortical tissue blood flow
Cortical wash in rate (WiR) measured in arbitrary unitsMeasured at enrollment, +24 hours and + 48 hoursContrast enhanced ultrasound measures of renal cortical tissue blood flow
Urinary oxygen tension (pO2) across 24 hours study period measured in millimetres of mercury (mmHg)Across 48 hour study periodMean urinary pO2

Other

MeasureTime frameDescription
Microvascular flow index (MFI) (unitless score from 0 to 3 where 3 is the value see in health)Measured at enrollment, +24 hours and + 48 hoursIncident dark field video microscopy measures of the systemic microcirculation
Syndecan 1, angiopoietin 1 & 2, Interleukin 6 & 8 (IL-6, IL-8) and tissue necrosis factor (TNF). All measured in nanograms per millilitre (ng/ml)Measured at enrollment and + 48 hoursBiomarker analysis - markers of inflammation and endothelial activation/function
Perfused vessel density (PVD) measured in millimetres per square millimetreMeasured at enrollment, +24 hours and + 48 hoursIncident dark field video microscopy measures of the systemic microcirculation

Countries

United Kingdom

Contacts

Primary ContactSam Hutchings
sam.hutchings@nhs.net+442032994957

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026